BACKGROUND: The genetic background, transmissibility and virulence of MRSA have been poorly investigated in the cystic fibrosis (CF) population. The aim of this multicentre study was to analyse MRSA strains isolated from CF patients attending nine Italian CF care centres during a two-year period (2004-2005). All CF patients infected by MRSA were included. METHOD: Antibiotic susceptibility testing, SCCmec typing, Panton-Valentine Leukocidin (PVL) production, and Multi Locus Sequence Typing (MLST) analysis were carried out on collected isolates (one strain per patient). RESULTS: One hundred and seventy-eight strains isolated from 2360 patients attending the participating centres were analysed. We detected 56 (31.4%) SCCmec IV PVL-negative strains, with a resistance rate of 80.3% to clindamycin and of 14.5% to trimethoprim/sulphamethoxazole. MLST analysis showed that many isolates belonged to known epidemic lineages. The largest clone grouping of 29 isolates from 6 centres had the genetic background (ST8-MRSA-IV) of the American lineages USA300 and USA500, thus demonstrating the diffusion of these strains in a population considered at risk for hospital associated infections. CONCLUSIONS: Known MRSA epidemic clones such as USA600, USA800, USA1100, and UK EMRSA-3 were described for the first time in Italy. The diffusion of MRSA strains with high pathogenic potential in the CF population suggests that analysis of the MRSA strains involved in pulmonary infections of these patients is needed.
BACKGROUND: The genetic background, transmissibility and virulence of MRSA have been poorly investigated in the cystic fibrosis (CF) population. The aim of this multicentre study was to analyse MRSA strains isolated from CF patients attending nine Italian CF care centres during a two-year period (2004-2005). All CF patients infected by MRSA were included. METHOD: Antibiotic susceptibility testing, SCCmec typing, Panton-Valentine Leukocidin (PVL) production, and Multi Locus Sequence Typing (MLST) analysis were carried out on collected isolates (one strain per patient). RESULTS: One hundred and seventy-eight strains isolated from 2360 patients attending the participating centres were analysed. We detected 56 (31.4%) SCCmec IV PVL-negative strains, with a resistance rate of 80.3% to clindamycin and of 14.5% to trimethoprim/sulphamethoxazole. MLST analysis showed that many isolates belonged to known epidemic lineages. The largest clone grouping of 29 isolates from 6 centres had the genetic background (ST8-MRSA-IV) of the American lineages USA300 and USA500, thus demonstrating the diffusion of these strains in a population considered at risk for hospital associated infections. CONCLUSIONS: Known MRSA epidemic clones such as USA600, USA800, USA1100, and UK EMRSA-3 were described for the first time in Italy. The diffusion of MRSA strains with high pathogenic potential in the CF population suggests that analysis of the MRSA strains involved in pulmonary infections of these patients is needed.
Authors: Daniel J Wolter; Julia C Emerson; Sharon McNamara; Anne M Buccat; Xuan Qin; Elizabeth Cochrane; Laura S Houston; Geraint B Rogers; Peter Marsh; Karandeep Prehar; Christopher E Pope; Marcella Blackledge; Eric Déziel; Kenneth D Bruce; Bonnie W Ramsey; Ronald L Gibson; Jane L Burns; Lucas R Hoffman Journal: Clin Infect Dis Date: 2013-04-26 Impact factor: 9.079
Authors: Meredith A Benson; Elizabeth A Ohneck; Chanelle Ryan; Francis Alonzo; Hannah Smith; Apurva Narechania; Sergios-Orestis Kolokotronis; Sarah W Satola; Anne-Catrin Uhlemann; Robert Sebra; Gintaras Deikus; Bo Shopsin; Paul J Planet; Victor J Torres Journal: Mol Microbiol Date: 2014-07-16 Impact factor: 3.501
Authors: Duha Al-Zubeidi; Patrick G Hogan; Mary Boyle; Carey-Ann D Burnham; Stephanie A Fritz Journal: Pediatr Infect Dis J Date: 2014-06 Impact factor: 2.129
Authors: Danielle F Lima; Renata Wf Cohen; Géssica A Rocha; Rodolpho M Albano; Elizabeth A Marques; Robson S Leão Journal: Mem Inst Oswaldo Cruz Date: 2017-01-01 Impact factor: 2.743